Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881860 | 0.94 | HCAR3 (0.52) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5104752 | 0.87 | MAPT (0.48) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5591926 | 0.87 | HCAR3 (0.47) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5095722 | 0.86 | HCAR3 (0.49) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5095713 | 0.84 | HCAR3 (0.49) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL3762305 | 0.83 | HPGD (0.58) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5598329 | 0.82 | HCAR3 (0.46) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5591708 | 0.82 | GPR119 (0.49) | HCAR3PKM | |
| SCHEMBL4468864 | 0.82 | PTGER4 (0.59) | ALDH1A1MAPTHTT | |
| SCHEMBL5095799 | 0.81 | HCAR3 (0.48) | HCAR3ALDH1A1MAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| EP-1636193-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | BTF3, TYMS, F3 | HCAR3 1962/4885ALDH1A1 1603/4885MAPT 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.